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SUMMARY Parasitic infections remain one of the most pressing global health con-
cerns of our day, affecting billions of people and producing unsustainable economic
burdens. The rise of drug-resistant parasites has created an urgent need to study
their biology in hopes of uncovering new potential drug targets. It has been estab-
lished that disrupting gene expression by interfering with lysine acetylation is detri-
mental to survival of apicomplexan (Toxoplasma gondii and Plasmodium spp.) and
kinetoplastid (Leishmania spp. and Trypanosoma spp.) parasites. As “readers” of
lysine acetylation, bromodomain proteins have emerged as key gene expression reg-
ulators and a promising new class of drug target. Here we review recent studies that
demonstrate the essential roles played by bromodomain-containing proteins in para-
site viability, invasion, and stage switching and present work showing the efﬁcacy of
bromodomain inhibitors as novel antiparasitic agents. In addition, we performed a
phylogenetic analysis of bromodomain proteins in representative pathogens, some
of which possess unique features that may be speciﬁc to parasite processes and use-
ful in future drug development.
KEYWORDS Toxoplasma, Plasmodium, malaria, trypanosomes, Leishmania,
epigenetics
INTRODUCTION
The epigenetic regulation of gene expression requires a wide spectrum of enzymeswith functions including the alteration of posttranslational modiﬁcations (PTMs) on
histones or reconﬁguration of nucleosomes. The vast array of different PTMs and
histone combinations has been postulated to constitute a code drafted by “writer” and
“eraser” enzymes (1). Importantly, there are also “reader” proteins that interpret this
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code by recognizing certain PTMs on speciﬁc residues of histone proteins. These reader
domains may recognize acetylated lysines (bromodomains [BRDs]) or methylated
lysines or arginines (e.g., chromodomains, PHD ﬁngers, and Tudor domains) (2). These
different factors work in concert to elicit changes in gene expression in response to
developmental or environmental changes. Pathogenic protozoan parasites often move
through complex life cycles involving multiple stages in more than one host. Conse-
quently, pathogenic parasites rely on epigenetic control mechanisms to ﬁne-tune gene
expression, facilitating adaptation to different hosts/tissues or stressful environments.
Emerging evidence has suggested that bromodomain-containing proteins are impor-
tant mediators of gene expression that may represent novel drug targets in protozoal
pathogens (3–5). This review discusses the various bromodomain proteins in represen-
tative parasites from the Apicomplexa and Euglenozoa phyla, providing novel insight
into the evolution of this protein family and how it may contribute to parasite biology
in the context of lysine acetylation signaling.
LYSINE ACETYLATION AND EPIGENETIC REGULATION OF GENE EXPRESSION
It is now well established that gene expression is regulated through covalent
modiﬁcation of histones. Addition or removal of chemical modiﬁcations such as acet-
ylation, methylation, or phosphorylation can alter the structure and charge of the
nucleosome (and thereby its interaction with DNA) or inﬂuence the recruitment of
transcriptional regulatory machinery (1). Acetylation of histones is one of the best-
studied modiﬁcations and is generally associated with transcriptional activation, al-
though recent evidence suggests that in some cases histone acetylation may also
mediate gene repression (6). Lysine acetyltransferases (KATs) generally facilitate gene
activation by opening the chromatin structure to provide access for various protein
complexes involved in gene transcription. Lysine deacetylases (KDACs) remove acetyl
groups, restoring the heterochromatic structure that is refractory to gene activation
(Fig. 1). Acetylation marks on histone tails can also serve as docking points for
transcriptional regulators, recruited via their acetyl-lysine “reader” domain (Fig. 1). One
of the best characterized “readers” that mediates protein-protein interaction through
acetyl-lysine recognition is the bromodomain.
BROMODOMAINS: THE ACETYLATED LYSINE READERS
The bromodomain was ﬁrst described in the characterization of the Drosophila
melanogaster nuclear remodeling brahma protein, a SWI/SNF ATPase homologue
known to activate gene expression (7), and was noted to be conserved on a number of
other proteins involved in transcriptional activation in humans and yeasts (8). The
structure of the bromodomain was ﬁrst resolved for the KAT p300/CBP-associated
factor (PCAF), which led to the discovery that it can act as a “reader” of acetylated lysine
FIG 1 Regulation of transcription by lysine acetylation. Nucleosomes in the deacetylated state form tightly packed
chromatin where transcription factors do not have access to regulatory sequences encoded in the DNA. The action of
lysine acetyltransferases (KATs) adds acetyl groups to lysine residues in the histone tails, leading to a more open
conformation of the chromatin and allowing access to the transcriptional machinery. Transcription may be further
enhanced by recruitment of bromodomains to speciﬁc acetylated lysines and subsequent recruitment of additional
transcriptional enhancers. Removal of the acetyl groups by lysine deacetylases (KDACs) restores chromatin to the
closed state that is restrictive to transcription.
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residues (9). Comprised of 110 amino acids, the bromodomain folds into a left-
handed bundle of four  helices linked by two variable-loop regions (BC and ZA) that
form a hydrophobic pocket for the acetylated lysine (10). The oxygen of the acetyl
carbonyl group of the acetyl-lysine is typically anchored by a hydrogen bond to the
amide nitrogen of an asparagine residue in the BC loop (11), and a tyrosine in the ZA
loop binds the acetyl-lysine with four water molecules (10).
The variability in sequence and length of the ZA and BC loops among bromodo-
mains likely contributes to recognition of speciﬁc targets dictated by the amino acids
ﬂanking acetylated lysine residues. Screening of 33 representative bromodomains
against histone-peptide arrays supports the idea that not all bromodomains are created
equal and that their binding activities can be inﬂuenced by amino acids ﬂanking the
target acetyl-lysine (10). Some bromodomains have afﬁnity for a broad range of
peptides, such as the bromodomain from PCAF and the transcriptional regulator SP140.
Other bromodomains are far less promiscuous; the bromodomain from the transcrip-
tional regulator tripartite motif containing 28 (TRIM28) speciﬁcally recognizes histone
H3 acetylated at lysine 37 (H3K37ac), while the bromodomain from the mixed-lineage
leukemia (MLL) methyltransferase has the highest afﬁnity for histone H2A acetylated at
lysine 15 (H2AK15ac). Finally, some bromodomains did not bind any histone peptides
at all, consistent with recent studies showing that lysine acetylation is much more
widespread within cells than ﬁrst appreciated, linking metabolism and cellular signaling
(12). Instances of bromodomains binding nonhistone acetyl-lysines include CREB bind-
ing protein (CREBBP), recognizing the acetylated lysine 382 on p53 in response to
cellular stress (13). Another example involves modulating the association of SNF2 with
the nucleosomal chromatin. Nucleosome-bound SNF2 can be acetylated by GCN5 on
K1493 and K1497; the SNF2 bromodomain has a higher afﬁnity for its own acetylated
lysines than for acetylated histones and will dissociate from the nucleosome and bind
to itself (14).
Bromodomain-containing proteins can further regulate transcription through mod-
iﬁcation of chromatin structure. Recently shown to possess KAT activity, BRD4 targets
residues H3 K122, resulting in nucleosome eviction and chromatin decompaction (15,
16). Appropriate chromatin structure in sperm is maintained by the related bromodo-
main and extraterminal (BET) family member BRDT (17). Functions of bromodomain
proteins also extend to DNA damage repair, which relies on rapid changes in chromatin
structure to repress normal gene transcription and provide access to DNA repair
complexes (18–21; reviewed in reference 22). The signiﬁcant contribution of bromodo-
main proteins to DNA repair is underscored by their redistribution in response to DNA
damage (18).
DEVELOPMENT OF BROMODOMAIN INHIBITORS
Given their importance in gene expression regulation, it is not surprising that a
number of bromodomain-containing proteins have been linked to disease, including
cancer, atherosclerosis, inﬂammation, cardiovascular disease, and diabetes (Table 1)
(reviewed in references 23 and 24). Consequently, bromodomains are being investi-
gated as potential drug targets. Several classes of bromodomain inhibitors that bind
within the hydrophobic pocket, resulting in the exclusion of acetyl-lysine, have been
reported. Many of the bromodomain inhibitors act as acetylated lysine analogues,
forming hydrogen bonds in the hydrophobic pocket in a manner similar to the binding
of the acetylated lysine (25–27).
The BET proteins contain tandem bromodomains in the C terminus and are major
regulators of gene transcription by tethering transcriptional complexes to acetylated
histones; as such, BET proteins have been a major focus of efforts to develop bromodo-
main inhibitors (25, 26, 28). The observation that thienodiazopines bind bromodomain
protein BRD4 led to the development of JQ1, which binds with high selectivity and
competes with acetylated histone peptides for the BRD4 bromodomains (25). JQ1 is
able to displace the BRD4-nuclear protein in testis (NUT) oncogene fusion protein from
chromatin, resulting in growth arrest of BRD4-NUT background carcinoma cells (25).
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JQ1 has been applied to other human diseases, including liver cancer, inﬂammatory
responses, and angiogenesis-related disease (29–31). Another BET family inhibitor,
I-BET151, was shown to disrupt expression of genes activated in the inﬂammatory
response to bacterial liposaccharide (LPS). Treatment of bone marrow-derived macro-
phages with I-BET151 led to downregulation of key LPS-stimulated cytokines and
chemokines (26). I-BET151 has also shown promise for treatment of many different
cancers in which cMYC is overexpressed due to the close regulatory relationship
between this oncogene and BET proteins (32–36). The initial studies with both JQ1 and
I-BET151 demonstrate that these synthetic compounds compete with acetylated lysines
for bromodomains, resulting in gene expression changes that provide promising
outcomes for several human diseases.
The tandem BRD arrangement of the BET family of proteins has prompted efforts to
develop even more potent BET inhibitors by linking two BET inhibitor molecules,
producing bivalent inhibitors that can simultaneously bind both BRDs in the BET
protein. Encouragingly, these molecules appear to retain their speciﬁcity to the BET
family but have signiﬁcantly improved potency over the single BRD binding com-
pounds (37, 38).
Small-molecule inhibitors of other bromodomain subtypes are now under develop-
ment, not only for treatment of human disease but also as useful tools to delineate the
functions of various bromodomain proteins. The association of the CREBBP bromodo-
main with acetylated p53 (13) has elicited interest in the utility of speciﬁc inhibitors of
this interaction. A compound library screen using nuclear magnetic resonance (NMR) to
assess binding to recombinant CREBBP bromodomain, followed by lead compound
TABLE 1 Commercially available bromodomain inhibitors and their targets
Inhibitor Target BRD(s) Disease(s) and/or activity(ies) Reference(s)
BET inhibitors
I-BET151 BRD2, BRD3, BRD4 Endotoxic shock and sepsis, MLL-fusion leukemia, inhibits
proliferation of T. cruzi and T. gondii, causes aberrant stage
switching in T. brucei
3, 5, 26, 103
I-BET762 BET Septic shock, neuroblastoma 104
()-JQ1 BET Hematological malignancies, solid tumors, activates latent HIV,
inhibits T. cruzi proliferation
5, 25, 49
PFI-1 BRD4 Anti-inﬂammatory, anti-lymphoma 105
OTX015 BET Leukemia and lymphoma, NMC, castration-resistant prostate cancer,
glioblastoma multiforme, activation of latent HIV
106–109
RVX 208 BET Atherosclerosis, cardiovascular disease, diabetes 110–112
CPI-203 BET Leukemia, pancreatic neuroendocrine tumors 113, 114
MS417 BET Anti-inﬂammatory, colorectal cancer, activation of latent HIV 48, 115, 116
MS 436 BRD4 Anti-inﬂammatory 117
XD 14 BRD4 Leukemia 118
OXF BD 02 BRD4 Leukemia 119
Non-BET BRD inhibitors
Ischemin CREBBP 39
SCG-CBP30 CREBBP/EP300 120
I-CBP 112 CREBBP/EP300
PF CBP1 CREBBP/EP300 Anti-inﬂammatory 40
BAZ2-ICR BAZ2A/BAZ2B 43
GSK 2801 BAZ2A/BAZ2B 44
GSK 5959 BRPD1 121
PFI-4 BRPF1 121
IACS-9571 TRIM24/BRPF1 122
LP99 BRD7/BRD9 Anti-inﬂammatory 123
BI 9564 BRD7, BRD9 Antitumor 124
I-BRD9 BRD9 125
PFI-3 SMARCA2, SMARCA4,
Polybromo 1
45, 126
Pan-BRD inhibitors
Bromosporine Broad spectrum 127
ISOX DUAL CREBBP/EP300, BRD4 40
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optimization, led to the identiﬁcation of ischemin, which displays at least 5-fold-greater
selectivity for the CREBBP bromodomain than for other human bromodomains (39). An
independent study to determine CREBBP bromodomain ligands identiﬁed the com-
pound PF-CBP1, which downregulates a speciﬁc subset of inﬂammatory genes in
macrophages that were unaffected during treatment with a BET-speciﬁc inhibitor (40).
The two closely related bromodomain-adjacent zinc ﬁnger (BAZ) bromodomain
proteins BAZ2A and BAZ2B play essential regulatory roles in chromatin remodeling and
have also been implicated in the regulation of noncoding RNAs (41, 42). Two indepen-
dent attempts at structure-based compound optimization based on two initially weak
inhibitors led to development of GSK2801 and BAZ2-ICR, selectively potent inhibitors of
both BAZ2A and BAZ2B (43, 44).
SMARCA2 and SMARCA4 (SWI/SNF-related, matrix-associated, actin-dependent reg-
ulator of chromatin, subfamily A, member 2 or 4) are mutually exclusive members of a
SWI/SNF chromatin-remodeling complex implicated in cellular differentiation and pro-
liferation and are both linked to a variety of different cancers. The inhibitor PFI-3
selectively binds the SMARCA4 bromodomain and displaces it from chromatin; how-
ever, these studies have shown that inhibition of the bromodomain binding to the
nucleosome alone is not sufﬁcient for preventing proliferation of tumor cells and that
inhibition of the ATPase activity of SMARCA4 is also required (45).
Pan-bromodomain inhibitors such as bromosporine and [1,2,4]triazolo[4,3-a]
phthalazines have demonstrated inhibitory activity for many different bromodomains
(46, 47). Their promiscuity suggests that they may be of limited value in the clinic, but
these compounds represent useful tools in dissecting bromodomain function in many
organisms.
The utility of bromodomain inhibitors in infectious disease has already been re-
vealed with studies aiming to completely eradicate HIV from patients by reactivating
the latent virus. The BET bromodomain BRD4 has been shown to suppress HIV
transcription through interaction with the positive transcription elongation factor b
(P-TEFb), sequestering P-TEFb from the viral protein transactivator of transcription (Tat),
which is essential for viral gene expression. Another BET family member, BRD2, was also
found to contribute to HIV latency through a Tat-independent mechanism that has yet
to be determined (48). When cells harboring latent HIV were treated with inhibitors of
the BET family, it led to reactivation of viral gene transcription (48–53).
The concept of targeting bromodomains to thwart human disease might also be
applicable to treating infections caused by eukaryotic pathogens. We and others have
identiﬁed numerous bromodomain-containing proteins in protozoa that are essential
for viability, including a subset of KATs, offering a new opportunity for the development
of antiparasitics. The study of bromodomains in these early-branching eukaryotic cells
is also revealing new insights into the evolution of this critical acetyl-lysine recognition
motif.
LYSINE ACETYLATION IN PROTOZOAN PARASITES
Parasitic protozoa present a devastating burden to global human and veterinary
health. As most of these diseases hit impoverished nations, they are neglected in terms
of research; there are few effective treatments, and those that do exist are seeing their
utility evaporate in the face of rampant drug resistance. Some of the major parasitic
diseases include malaria (caused by Plasmodium spp.), toxoplasmosis (Toxoplasma
gondii), the diarrheal disease cryptosporidiosis (Cryptosporidium spp.), African trypano-
somiasis/sleeping sickness (Trypanosoma brucei), American trypanosomiasis/Chagas
disease (Trypanosoma cruzi), and leishmaniasis (Leishmania spp.).
The importance of histone acetylation in apicomplexan parasites (Plasmodium spp.,
Toxoplasma gondii, and Cryptosporidium spp.) was ﬁrst demonstrated in 1996 with the
discovery of apicidin, a natural product that proved “cidal” against apicomplexan
parasites and was subsequently found to be a histone deacetylase inhibitor (54). Later
studies revealed extensive lysine acetylation machinery in these parasites that could be
targeted with additional deacetylase inhibitors (55–59) or KAT inhibitors (60–63). More
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recent discoveries suggest that, in addition to perturbing gene expression patterns,
these inhibitors could be interfering with cellular signaling in the parasite nucleus and
beyond. Proteome-wide surveys have uncovered hundreds of parasite proteins in T.
gondii and Plasmodium falciparum that are subject to lysine acetylation in every
subcellular compartment (64–66).
There is also evidence that lysine acetylation is critical in kinetoplastids (Trypano-
soma spp. and Leishmania spp.), although these parasites have a very unusual mech-
anism of gene regulation. The kinetoplastid genome is arranged in gene clusters, and
transcription produces polycistronic transcripts. Regulation of gene expression appears
to be primarily posttranscriptional, via modulation of the splicing machinery that
generates the mature mRNAs (67). Moreover, their histone sequences and the PTMs
that decorate them deviate from what is observed in other eukaryotes (68–72). For
example, histone H3 is relatively free of acetylation, the majority of modiﬁcations that
have been identiﬁed are found on H4, and the C-terminal tail of histone H2A is heavily
acetylated in T. brucei (71). Nevertheless, the kinetoplastids clearly use histone acety-
lation to regulate synthesis of the polycistronic transcripts (73, 74). Underscoring the
pharmacological relevance of lysine acetylation in kinetoplastids are studies showing
efﬁcacy of some KDAC inhibitors against T. brucei, T. cruzi, and Leishmania donovani
(75–78).
BROMODOMAIN PROTEINS IN PROTOZOAN PARASITES
Toxoplasma gondii
The ﬁrst bromodomain-containing protein in protozoan parasites was identiﬁed
with the discovery of a GCN5 family KAT in T. gondii (79, 80). T. gondii is unique in that
it possesses two nuclear GCN5 KATs, each harboring a bromodomain near the
C-terminal end of the protein (81). T. gondii GCN5a (TgGCN5a), while not essential in the
replicative stage (tachyzoite) of the parasite, appears to contribute to the transition to
the latent tissue cyst stage (bradyzoite) (82). The discovery that bromodomain proteins
are involved in parasite differentiation is particularly important given the profound role
that tissue cysts have in transmission and pathogenesis of T. gondii (83). In contrast,
TgGCN5b is refractory to genetic disruption, suggesting that it is essential for tachyzoite
replication. Inducible expression of a KAT-dead form of GCN5b acts as a dominant
negative, leading to dysregulation of gene expression and parasite growth arrest (84).
GCN5b is found in association with AP2 proteins (plant-like transcription factors present
in Apicomplexa), the ADA2-A coactivator, and members of the TFIID complex, including
another bromodomain-containing protein (TAF1). It is presumed that the TgGCN5
bromodomains function to bind acetylated lysines on histone tails (10, 85) in order to
anchor the GCN5 complex to nucleosomes at target promoters, as seen for the yeast
GCN5 complex (86).
In addition to those for GCN5a, GCN5b, and TAF1, there are nine other genes
encoding proteins with predicted bromodomains in the T. gondii genome (ToxoDB.org)
(Table 2). Another putative member of the TFIID complex, TAF2, contains a C-terminal
bromodomain. There is also a predicted SET1 homologue with lysine methyltransferase
activity, in addition to a number of PHD ﬁnger domains that may also function as PTM
“readers.” These domains may act in concert with the bromodomain to target the SET1
methyltransferase activity to speciﬁc loci on the chromatin.
Plasmodium falciparum
There are seven bromodomain-containing proteins in the P. falciparum genome, and
two have been characterized to date. Unlike for T. gondii, only a single GCN5 (PfGCN5)
has been identiﬁed in Plasmodium species, but it does contain a single C-terminal
bromodomain. As seen for both T. gondii GCN5s, PfGCN5 also displays a preference to
acetylate lysine residues in the histone H3 tail, and it appears to be essential for
blood-stage replication (87).
The domain architecture of P. falciparum bromodomain protein 1 (PfBDP1) contains
a single C-terminal bromodomain and a number of ankyrin repeats; this architecture is
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conserved in the probable T. gondii orthologue (TGME49_263580) and appears to be
unique to apicomplexan parasites. Inducible knockdown of PfBDP1 resulted in parasites
that were unable penetrate red blood cells (4). This invasion defect was concurrent with
deregulation of invasion-associated genes after PfBDP1 knockdown. Chromatin immu-
noprecipitation sequencing (ChIP-seq) revealed that PfBDP1 associates with sequences
upstream of these invasion-associated genes to activate their expression. Microscale
thermophoresis experiments showed that PfBDP1 preferentially binds H3K9ac and
H3K14ac, consistent with the role of this protein in gene activation. Coimmunoprecipi-
tation revealed that PfBDP1 interacts with a set of nuclear proteins, including another
bromodomain protein (PfBDP2) and an AP2 protein (PF3D7_0613800). Together, these
ﬁndings are consistent with the idea that PfBDP1 acts like other bromodomain proteins
in higher eukaryotes by tethering a transcriptional activator complex to acetylated H3
to control genes required for parasite invasion. It will be of interest to see if other
bromodomain proteins in Plasmodium associate with discrete subsets of genes.
There are ﬁve additional predicted bromodomain proteins in P. falciparum
(PlasmoDB.org) (Table 2). Similar to the case for T. gondii, the predicted SET1 homo-
logue also contains an N-terminal bromodomain in combination with a number of PHD
ﬁnger domains. The only other bromodomain-containing protein in Plasmodium with
any known homology is the TFIID complex member TAF1.
TABLE 2 Bromodomain proteins in protozoan parasites
Species and gene
ID Annotation
Protein
name Localization
Other
domain(s) Function Reference
P. falciparum
PF3D7_0629700 SET domain protein, putative PfSET1
PF3D7_0823300 Histone acetyltransferase GCN5 PfGCN5 Nuclear KAT Histone acetylation 87
PF3D7_1234100 Bromodomain protein, putative TAF1 Nuclear KAT TFIID complex of RNA polymerase II 94
PF3D7_1033700 Bromodomain protein 1 PfBDP1 Nuclear Ankyrin repeats Regulation of invasion-related
genes
4
PF3D7_1212900 Bromodomain protein 2, putative PfBDP2 Associated with PfBDF1 4
PF3D7_0110500 Bromodomain protein, putative PfBDP3
PF3D7_1475600 Bromodomain protein, putative PfBDP4
T. gondii
TGME49_254555 Histone lysine acetyltransferase
GCN5-A
TgGCN5a Nuclear KAT Histone acetylation 82
TGME49_243440 Histone lysine acetyltransferase
GCN5-B
TgGCN5b Nuclear KAT Essential, histone acetylation 84
TGME49_276180 Histone acetyltransferase TAF1/250 TAF1/250 KAT TFIID complex of RNA polymerase II 95
TGME49_214240 Bromodomain-containing protein TAF2/150 TFIID complex of RNA polymerase II
TGME49_226810 Histone lysine methyltransferase
SET1
TgSET1 SET, PHD
TGME49_278440 SWI2/SNF2 brahma-like putative TgBRG1 DEXDc, helicase
TGME49_263580 Bromodomain-containing protein TgBDP1 Ankyrin repeats
TGME49_264640 Bromodomain-containing protein TgBDP2
TGME49_258990 Bromodomain-containing protein TgBDP3
TGME49_306460 Bromodomain-containing protein TgBDP4
TGME49_264020 Hypothetical protein TgBDP5
TGME49_311625 WD domain, G-beta repeat-
containing protein
TgBDP6 WD40, PHD
T. cruzi
TcCLB.506247.80 DNA binding protein, putative TcBDF1 Glycosome 90
TcCLB.506553.20 Bromodomain factor 2 protein TcBDF2 Nuclear Binds acetylated H4, accumulates
after UV irradiation
88
TcCLB.510719.70 Bromodomain-containing protein 3 TcBDF3 Cytoplasm, ﬂagellum 91
TcCLB.504213.70 Hypothetical protein, conserved TcBDF4 Nuclear
TcCLB.506755.120 hypothetical protein, conserved TcBDF5 Nuclear
T. brucei
Tb927.10.8150 Predicted bromodomain protein TbBDF1
Tb927.10.7420 Bromodomain factor 2 protein,
putative
TbBDF2 Regulation of VSG expression 3
Tb927.11.10070 Bromodomain, putative TbBDF3 Regulation of VSG expression 3
Tb927.7.4380 Bromodomain, putative TbBDF4 Zinc ﬁnger
Tb927.11.13400 Bromodomain, putative TbBDF5 Nuclear Regulation of VSG expression 93
Tb927.1.3400 Hypothetical protein, conserved TbBDF6
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Trypanosoma cruzi
Five bromodomain proteins (TcBDF1 to -5) have been identiﬁed in the T. cruzi
genome (Table 2). The ﬁrst to be described was TcBDF2, which is expressed throughout
the life cycle in the parasite nucleus and associates with chromatin through interactions
with H4K10ac and H4K14ac. Little is known about the biological function of TcBDF2
other than that its levels increase following UV irradiation (88), so it may be involved in
coordinating a response to DNA damage.
While most bromodomain proteins are found predominantly in the nucleus, TcBDF1
and TcBDF3 are not nuclearly localized. TcBDF1 is expressed throughout the life cycle
but is found at higher levels in the trypomastigotes, which are responsible for infection
and dissemination in humans, than in the replicative, intracellular amastigotes or the
epimastigotes, which infect the insect vector. Microscopy and cellular fractionation
conﬁrmed that TcBDF1 localizes to the parasite glycosome, a peroxisome-like organelle
that is unique to kinetoplastids and required for biochemical processes related to
glucose metabolism (89). Although the exact function and associated factors of TcBDF1
remain unknown, its importance for parasite viability was indicated by studies dem-
onstrating that overexpression of the protein in epimastigotes led to growth arrest and
parasite death (90). A mutant version of TcBDF1 had no effect on epimastigote growth
but negatively impacted trypomastigote infection and amastigote replication (90). How
these phenotypes relate to the localization of TcBDF1 at glycosomes, or the ability of
the protein to bind acetylated lysines, remains to be elucidated.
TcBDF3 is also expressed in all T. cruzi life cycle stages and is notably associated with
the parasite ﬂagellum, possibly through association with acetylated -tubulin (91).
Acetylated -tubulin is conserved across eukaryotes, yet no other bromodomain pro-
tein has been found to interact with this PTM. Overexpression of wild-type TcBDF3 had
no effect on parasite replication, but overexpression of a TcBDF3 mutant unable to bind
acetylated lysines impaired growth of insect-stage epimastigotes (5). The appearance of
aﬂagellated parasites during overexpression of mutant TcBDF3 suggests that this
bromodomain protein contributes to the formation and/or maintenance of ﬂagella in
epimastigotes. Curiously, mutant TcBDF3 still localized to microtubules, suggesting that
its association with the cytoskeleton occurs independently of its ability to bind acety-
lated lysines (5).
Trypanosoma brucei
T. brucei possesses six bromodomain proteins (TbBDF1 to -6) (Table 2), at least four
of which are nuclear: TbBDF1, TbBDF2, TbBDF3, and TbBDF5 (92). TbBDF3 colocalizes
with H4K10ac, enriched in a narrow region at the 5= end of probable RNA polymerase
II transcriptional start sites (TSSs). The authors proposed a model whereby TbBDF3 is
recruited to RNA polymerase II TSSs by H4K10ac, which results in a subsequent
recruitment of general transcription factors and chromatin-remodeling complexes to
the TSS, in a manner similar to that for BDF1 in yeast. RNA interference (RNAi)
knockdown of TbBDF3 led to a parasite growth defect and death (92).
Additional ChIP-seq studies performed by Schulz and colleagues conﬁrmed the
association of TbBDF3 with TSSs, along with TbBDF1 and TbBDF4; however, TbBDF2 did
not localize to TSSs (3). Genetically engineered parasites lacking TbBDF2 or TgBDF3
exhibited impaired growth in vitro, with RNA-seq showing signiﬁcant upregulation of
variant surface glycoproteins (VSGs) located at silent bloodstream expression sites.
VSGs are crucial for T. brucei to maintain a bloodstream infection in its mammalian host.
The parasite carries a large repertoire of genes encoding variants of these surface
proteins but expresses only a single variant at a time. The immune system of the host
will mount a response against the VSG, upon which the parasite will switch to express
an alternative VSG for immune evasion. Epigenetic regulation is critical for monoallelic
expression of VSGs, and these data support an important role for bromodomains in
maintaining monoallelic expression of VSG genes. Loss of either TbBDF2 or TbBDF3 also
caused a dysregulation in parasite stage-speciﬁc gene expression, leading to upregu-
lation of transcripts speciﬁc to the parasite insect stage. The importance of bromodo-
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main proteins in maintenance of host-appropriate gene expression was validated by
the observation that treatment with a bromodomain inhibitor severely compromised in
vivo infection in mouse models (3).
Results from a genome-scale RNA interference viability screen revealed a potential
role for TbBDF5 in regulating VSG gene expression sites (93). TbBDF5 localizes to the
nucleus, and knockdown in both bloodstream and insect stages causes severe growth
defects, indicating an essential regulatory function for TbBDF5 that has yet to be
resolved.
Table 2 lists the bromodomain proteins for the species described above, along with
what is currently known about localization and function. While there is some degree of
conservation in function for some of the parasite bromodomain proteins, a number of
species-speciﬁc bromodomains have arisen. We performed a phylogenetic analysis (see
the next section) to shed more light on the bromodomain proteins among these
parasite species.
CONSERVATION OF BROMODOMAINS IN PROTOZOAN PARASITES
To investigate the relationships of the 29 bromodomain-containing proteins from
the four protozoan parasites P. falciparum, T. gondii, T. brucei, and T. cruzi, we performed
a phylogenetic analysis of the bromodomain sequences, which are aligned in Fig. 2
Reciprocal BLAST searches of only the bromodomain sequence were combined with
BLAST searches of the entire protein sequence, followed by manual curation of the two
analyses to identify the most closely related bromodomain factors in these species. The
ﬁnal phylogenetic tree clustered these proteins into six groups, with three groups
containing proteins from all four species (Fig. 3).
The ﬁrst group contains the two GCN5s in T. gondii and the single GCN5 in P.
falciparum, with each possessing one C-terminal bromodomain and one KAT domain.
The bromodomains from both TgGCN5a (reciprocal blast E values, 3e156 and
7e162) and TgGCN5b (2.00e173 and 2e167) show even higher similarities with the
bromodomain from PfGCN5 compared to each other (1e144 and 3e148). The close
relationship of the essential KATs PfGCN5 and TgGCN5b suggests that these may carry
out a housekeeping function, while TgGCN5a arose to perform a regulatory function
FIG 2 Alignment of bromodomain sequences found in representative parasites. Protein sequence alignments were performed in MUSCLE, and further
alignments were modiﬁed by the predicted three-dimensional structure of each sequence with STRAP. The conserved blocks of the ﬁnal alignments were
selected by Gblocks 0.91b for tree-building (highlighted in blue). Phylogenetic analysis was performed with a maximum-likelihood method using PHYML 3.0
with the LG model. Branch support values were estimated by the approximate likelihood-ratio test (aLRT). The conserved tyrosine (Y) and asparagine (N)
residues that mediate interaction with the acetylated lysine are highlighted with asterisks and shaded boxes. The ﬁrst two letters of each accession number
designate the species, as follows: Tg, Toxoplasma gondii; Pf, Plasmodium falciparum; Tb, Trypanosoma brucei; Tc, Trypanosoma cruzi.
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that is unique to T. gondii (e.g., stage switching in response to stress [82]). We included
the BDF2s from the two trypanosome parasites in this group because they reciprocally
best match TgGCN5b and PfGCN5, suggesting some homology and potentially a
comparable acetylated lysine substrate. Interestingly, trypanosome species lack a clear
GCN5 homologue, making it tempting to speculate that BDF2 pairs with a different KAT
to form a GCN5-like complex that has both a KAT domain and bromodomain. Group II
is the largest grouping of parasite bromodomain proteins, containing three pairs of
homologues between T. gondii and P. falciparum, including PfBDP1 and PfBDP2, and a
pair of homologues from the two trypanosome species, TbBDF3 and TcBDF3. The
proteins in this group do not show particularly high similarities but are most closely
related compared with the other bromodomain sequences.
Group II members do not contain any other functional domains, with the exception
of PfBDP1 and the related TgBDP1, which contain ankyrin domains in the N-terminal
portion of the protein, presumably operating in protein-protein interactions.
Group III is comprised of the trypanosome BDF1 homologues, which cluster with
two uncharacterized bromodomain proteins present in P. falciparum and T. gondii;
members of this clade carry a single bromodomain in the N terminus, suggesting a
common function. Also in this group are the apicomplexan TAF1 homologues (94, 95).
FIG 3 Phylogenetic analysis of protozoan bromodomains. The 29 bromodomains (BRDs) identiﬁed among the four parasite species shown
in Fig. 2 clustered into six main clades with three outlier proteins from T. gondii. The domain architecture of each bromodomain protein
is displayed to the right of the dendrogram. aa, amino acids.
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Two bromodomain proteins unique to the apicomplexan species also harbor
C-terminal SET methyltransferase domains (group IV) that, based on domain architec-
ture, appear to be homologues of the mixed-lineage leukemia (MLL) family of meth-
yltransferases; these bromodomain proteins are the only ones examined that also have
multiple PHD ﬁngers, another domain that can act as a histone PTM “reader” (96).
Groups V and VI consist only of two homologous pairs of trypanosome proteins,
BDF4 and BDF5, with signiﬁcant similarities within each pair. The remaining three
bromodomain proteins from T. gondii are not related to any other sequences investi-
gated. It is surprising that only the T. gondii homologue of the putative SWI2/SNF2
protein TGME49_278440 contains a bromodomain. This family of chromatin remodelers
contains a C-terminal bromodomain in higher eukaryotes, yet the homologues in the
other protozoal species examined lack this domain. It is also signiﬁcant that the
remaining two bromodomains do not contain the conserved asparagine residue re-
quired for acetyl-lysine recognition. In TgBDP6, the position of the conserved aspara-
gine is occupied by an aspartic acid (Fig. 2), which has been reported for some atypical
bromodomain proteins such as MLL (97). Interestingly, a cysteine is located in the
position of the conserved asparagine in TgBDP5, which has not been reported to date;
experimental validation is required to conﬁrm if this bromodomain binds acetylated
lysines.
BROMODOMAIN INHIBITION IN PROTOZOAN PARASITES
As mentioned above, several bromodomain inhibitors have been developed in
hopes of treating multiple types of disease by interfering with lysine acetylation
signaling. We may be able to add infections caused by protozoan parasites to this list,
as genetic studies have shown that most parasite bromodomain proteins are crucial for
viability and virulence. Some studies have already begun to examine the effects of
bromodomain inhibitors against these protozoan parasites, and these complement
previous work showing the antiparasitic activities of KAT and KDAC inhibitors (55–63).
The effects of seven bromodomain inhibitors on T. cruzi have been assessed, and
three (JQ1, I-BET151, and GSC-CBP30) displayed promising inhibitory effects on parasite
replication. These inhibitors were shown to interact with the bromodomain of TcBDF3,
and overexpression of the protein decreased parasite sensitivity to the compounds (5).
I-BET151 helped identify a critical role for T. brucei bromodomain proteins in the
maintenance of the bloodstream stage, which includes immune evasion through
retention of monoallelic VSG gene expression (3). However, I-BET151 impacts human
bromodomain proteins that affect host immunity, which may preclude its use against
infections (26). Further characterization of parasite bromodomains is needed to de-
velop more speciﬁc inhibitors against those that are required for in vivo pathogenesis.
Recently, TbBRD2 was crystallized with I-BET151 and revealed a novel, ﬂipped binding
mode of this inhibitor, underscoring the value of this approach toward rational drug
design (26).
Preliminary studies of bromodomain inhibitors in T. gondii have also shown I-BET151
to be a potent inhibitor of tachyzoite replication (128). At present, bromodomain
inhibitors have not been analyzed for potential activity against Plasmodium.
FUTURE DIRECTIONS
The functions of the bromodomain proteins in parasitic protozoa are just beginning
to be uncovered. The development of high-throughput and sensitive proteomics
technologies as well as the introduction of the genomic editing tool CRISPR/Cas9 will
facilitate closer inspection of the biological processes that these proteins regulate. The
remarkable discovery of bromodomain proteins outside the nucleus in T. cruzi, coupled
with the growing catalogue of acetylation marks on proteins involved in many different
functions, implies that bromodomain inhibitors could effectively perturb multiple
cellular pathways in the parasites.
Protein binding arrays, such as those used for the human bromodomains (10), can
be applied to parasite bromodomains in order to determine the acetylated lysine
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substrates that these proteins recognize, which will help unravel the precise signaling
pathways that are regulated by each factor. It will be of particular interest to identify
the substrates of the nonnuclear bromodomain factors, as these functions will likely be
unique to the protozoans.
There is emerging evidence that other domains are capable of acetylated lysine
recognition, such as the double PHD ﬁnger and double pleckstrin domains and the
YEATs domain (98–102). Combing the available parasite genome sequences will un-
cover any parasite homologues of these factors that may also prove to be valuable
targets for inhibiting lysine acetylation pathways. Novel acetylation recognition do-
mains may be revealed by probing parasite lysates with immobilized acetylated pep-
tides to identify the parasite proteins that bind the acetyl mark.
The bromodomains and other reader domains that are essential to parasite prolif-
eration and development could be screened against compound libraries to identify
lead compounds. These inhibitors will be invaluable for drug development but will also
be useful tools for further dissection of bromodomain function in protozoans. Ongoing
development of bromodomain inhibitors for human disease will generate a multitude
of bromodomain binding compound libraries that may then be screened for selective
activity against parasite bromodomains. This offers a tantalizing opportunity to develop
effective antiparasitic therapies with minimal side effects to help alleviate the heavy
burden of parasitic disease.
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